4-tert-Butoxybenzylsulfonylacetic acid | 1005494-33-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-tert-Butoxybenzylsulfonylacetic acid
• 英文别名: 2-[[4-[(2-Methylpropan-2-yl)oxy]phenyl]methylsulfonyl]acetic acid
• CAS: 1005494-33-6
• 化学式: C₁₃H₁₈O₅S
• 分子量: 286.349
• InChiKey: JGZMFJMUBCTDSH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  89
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-tert-Butoxybenzylsulfonylacetic acid 、 2,4,6-三甲氧基苯甲醛 在 苄胺 溶剂黄146 作用下， 以52%的产率得到(E)-2,4,6-trimethoxystyryl-4-hydroxybenzylsulfone
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of (E)-Styrylbenzylsulfones as Novel Anticancer Agents

  摘要：

  Cell cycle progression is regulated by cyclins and cyclin-dependent kinases, which are formed at specific stages of the cell cycle and regulate the G1/S and G2/M phase transitions, employing a series of "checkpoints" governed by phosphorylation of their substrates. Tumor development is associated with the loss of these checkpoint controls, and this provides an approach for the development of therapeutic agents that can specifically target tumor cells. Here, we describe the synthesis and SAR of a novel group of cytotoxic molecules that selectively induce growth arrest of normal cells in the G1 phase while inducing a mitotic arrest of tumor cells resulting in selective killing of tumor cell populations with little or no effect on normal cell viability. The broad spectrum of antitumor activity in vitro and xenograft models, lack of in vivo toxicity, and drug resistance suggest potential for use of these agents in cancer therapy.

  DOI：

  10.1021/jm701077b
• 作为产物：
  描述：

  2-[[4-[(2-methylpropan-2-yl)oxy]phenyl]methylsulfanyl]acetic acid 在 双氧水 、 溶剂黄146 作用下， 反应 18.0h， 生成 4-tert-Butoxybenzylsulfonylacetic acid
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of (E)-Styrylbenzylsulfones as Novel Anticancer Agents

  摘要：

  Cell cycle progression is regulated by cyclins and cyclin-dependent kinases, which are formed at specific stages of the cell cycle and regulate the G1/S and G2/M phase transitions, employing a series of "checkpoints" governed by phosphorylation of their substrates. Tumor development is associated with the loss of these checkpoint controls, and this provides an approach for the development of therapeutic agents that can specifically target tumor cells. Here, we describe the synthesis and SAR of a novel group of cytotoxic molecules that selectively induce growth arrest of normal cells in the G1 phase while inducing a mitotic arrest of tumor cells resulting in selective killing of tumor cell populations with little or no effect on normal cell viability. The broad spectrum of antitumor activity in vitro and xenograft models, lack of in vivo toxicity, and drug resistance suggest potential for use of these agents in cancer therapy.

  DOI：

  10.1021/jm701077b

文献信息

• PROCESSES FOR PREPARING (E)-STYRYLBENZYLSULFONE COMPOUNDS AND USES THEREOF FOR TREATING PROLIFERATIVE DISORDERS
  申请人：SIRIGIREDDY REDDY

  公开号：US20100152491A1

  公开（公告）日：2010-06-17

  Processes for preparing (E)-2,4,6-(Trimethoxystyryl)-3-O-Phosphate Disodium-4-Methoxybenzyl Sulfones and uses thereof as antiproliferative agents, including, for example, anticancer agents, and as radioprotective and chemoprotective agents.

  制备(E)-2,4,6-(三甲氧基苯乙烯基)-3-O-磷酸二钠-4-甲氧基苯甲基磺酮的方法及其作为抗增殖剂的用途，包括作为抗癌剂，以及作为放射保护和化学保护剂的用途。
• US8735620B2
  申请人：——

  公开号：US8735620B2

  公开（公告）日：2014-05-27
• Design, Synthesis, and Biological Evaluation of (<i>E</i>)-Styrylbenzylsulfones as Novel Anticancer Agents
  作者：M. V. Ramana Reddy、Muralidhar R. Mallireddigari、Stephen C. Cosenza、Venkat R. Pallela、Nabisa M. Iqbal、Kimberly A. Robell、Anthony D. Kang、E. Premkumar Reddy

  DOI：10.1021/jm701077b

  日期：2008.1.1

  Cell cycle progression is regulated by cyclins and cyclin-dependent kinases, which are formed at specific stages of the cell cycle and regulate the G1/S and G2/M phase transitions, employing a series of "checkpoints" governed by phosphorylation of their substrates. Tumor development is associated with the loss of these checkpoint controls, and this provides an approach for the development of therapeutic agents that can specifically target tumor cells. Here, we describe the synthesis and SAR of a novel group of cytotoxic molecules that selectively induce growth arrest of normal cells in the G1 phase while inducing a mitotic arrest of tumor cells resulting in selective killing of tumor cell populations with little or no effect on normal cell viability. The broad spectrum of antitumor activity in vitro and xenograft models, lack of in vivo toxicity, and drug resistance suggest potential for use of these agents in cancer therapy.